Preclinical data had suggested reducing serotonin might improve symptoms of pulmonary arterial hypertension, but new phase 2b ...

A study in mice finds that blocking somatostatin could restore the ability of the pancreas to release glucagon in the event ...

Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis ...

Less than a quarter of menopausal women have their menopause symptoms entered into their charts at primary care visits, ...

Sen. J.D. Vance credited Donald Trump with "salvaging" the Affordable Care Act (ACA). Gov. Tim Walz said Trump worked to ...

Some study results tempered enthusiasm for one digital therapeutic but others are showing promising if early results.

In 2025, Aetna will merge its three stand-alone prescription drug plans into a single plan and member cost-shares will be ...

Blue Shield of California is purchasing Idacio for a net price of $525 per monthly dose, and most plan members will pay $0 ...

VX-880 is an allogeneic stem cell-derived islet cell therapy that has been able to control blood glucose as well as natural ...

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that ...

Reference ustekinumab was originally approved by the FDA in 2009. Wezlana (ustekinumab-auub) was approved last October.

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...